同源康医药-B完成配售923万股 净筹约1.55亿港元

Core Viewpoint - Company completed the placement agreement conditions and successfully placed 9.23 million shares at a price of HKD 17.01 per share, raising approximately HKD 157 million in total proceeds [1] Fund Allocation - Approximately 60% of the net proceeds from the placement, around HKD 93 million, will be used for the research and commercialization of existing pipelines [1] - About 30% of the net proceeds, approximately HKD 46.5 million, will be allocated to enhance internal research capabilities and expand the product portfolio [1] - The remaining 10% of the net proceeds, around HKD 15.5 million, will be utilized for working capital and general corporate purposes [1]